Expect Trikafta to Be a Game Changer for Cystic Fibrosis

February 2020

Trikafta (try-KAF-tuh, elexacaftor/tezacaftor/ivacaftor) will be a game changer for treating cystic fibrosis (CF).

It targets a gene mutation found in nearly 90% of CF patients.

CF transmembrane conductance regulator (CFTR) modulators already on the market...Kalydeco, Orkambi, and Symdeko...target genetic mutations found in fewer than 50% of patients.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Seizures Consider Levetiracetam for Benzo-Resistant Status Epilepticus
New Drugs Save Recarbrio as a Last Resort for Resistant Infections
Emergency Medicine Be Ready to Manage Symptoms of Stimulant Toxicity
CPR Don't Expect to Add the Antiarrhythmic Bretylium to Crash Carts
Med Administration Know Whether to Redose Meds After Vomiting
New Drugs Expect Trikafta to Be a Game Changer for Cystic Fibrosis
Cardiology Help With Proper Use of Colchicine for Pericarditis
Hepatitis C Try to Limit Interruptions of Hep C Antivirals
New Drugs Watch for Patients on the Parkinson's Med Nourianz
Med Safety Recommend Eye Exams for Patients on Elmiron at Home